21-羟化酶缺陷所致经典先天性肾上腺皮质增生症婴幼儿及儿童的临床表现与治疗挑战
本文综述21-羟化酶缺陷所致经典先天性肾上腺皮质增生症婴幼儿及儿童的临床表现、推荐治疗、监测、临床挑战及特殊情境管理策略,涵盖新生儿筛查与初始诊断、糖皮质激素与盐皮质激素治疗及监测,并讨论心理社会与手术考量。
要点
- 21-羟化酶缺陷是先天性肾上腺皮质增生症最常见病因。
- 患儿可能出现肾上腺功能早现、性早熟、生长板提前闭合,高血压和超重/肥胖风险增加。
- 许多46,XX个体存在生殖器差异,包括阴蒂增大和/或尿生殖窦。
核心结论
- 本文综述了21-羟化酶缺陷所致经典先天性肾上腺皮质增生症婴幼儿及儿童的临床表现、推荐治疗、监测、临床挑战及特殊情境管理策略。
研究设计与样本
- 本文为综述,总结21-羟化酶缺陷所致经典先天性肾上腺皮质增生症婴幼儿及儿童的临床表现、推荐治疗、监测、临床挑战和管理策略。
主要发现
- 患儿可能出现肾上腺功能早现、性早熟和生长板提前闭合,高血压和超重/肥胖风险增加。
- 许多46,XX个体存在生殖器差异,可能包括阴蒂增大和/或尿生殖窦。
临床怎么用
- 文中关于如何与儿童、家庭及照护者谈论身体差异的建议可供家庭和/或照护先天性肾上腺皮质增生症个体的提供者使用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most common form of congenital adrenal hyperplasia (CAH) is secondary to 21-hydroxylase deficiency (21OHD). This review will summarize the clinical manifestations, recommended treatments, monitoring, clinical challenges and management strategy, and treatment challenges in special situations for infants and children with classic CAH due to 21OHD. Specifically, we review newborn screening and the initial diagnosis, glucocorticoid and mineralocorticoid treatment, and recommended monitoring, including anthropometric and laboratory measures. Children with CAH may have premature adrenarche, precocious puberty, and early growth plate closure and have an increased risk of hypertension and overweight/obesity. Many 46,XX individuals will also have genital differences, which may include clitoromegaly and/or a urogenital sinus. We review psychosocial and surgical considerations, including suggestions on how to talk with children, family, and caregivers about bodily difference. These suggestions may be used by families and/or providers caring for individuals with CAH.
引用
- Nokoff NJ, Buchanan C, Barker JM, et al. Clinical Manifestations and Treatment Challenges in Infants and Children With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2025. PMID: 39836622. doi:10.1210/clinem/dgae563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。